"Forthcoming medications take the blockbuster GLP-1 medications and up the ante." A new triple-action injection from Eli Lilly Why it's interesting: Retatrutide is a next-gen medication that acts on ...
Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...
Eli Lilly sued the Health Resources and Services Administration (HRSA) for allegedly blocking the pharma giant's proposal to ...
Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...
The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that ...
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback